inclusion criteria: * i1. male or female ≥ 18 years * greater than or equal to 70 years of age with or without any risk factor * or less than 70 years of age and the presence of at least one of the following risk factors: * arterial hypertension under treatment (all stages) * obesity (body mass index \[bmi\] ≥30 kg/m²) or severe obesity (bmi of ≥40 kg/m²) * diabetes (all types) * heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension) * stroke or cerebrovascular disease history * chronic lung diseases, including copd (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertension * malignancies (solid tumors or blood malignancies) that are progressive or were diagnosed less than 5 years ago * immunocompromised state (this includes patients who are suffering from primary immunodeficiencies; patients under treatment with corticosteroids either oral or parenteral; patients receiving active chemotherapy; patients on biological treatment or treatment with janus kinase (jak) inhibitors) * solid organ or blood stem cell transplant * down syndrome * known human immunodeficiency virus (hiv) infection * liver disease of stage 1 and 2 based on the child-pugh classification (appendix c) * hemoglobin blood disorders (thalassemia, sickle cell disease, etc) * renal disease (grade 1 and 2 according to kidney disease improving global outcomes (kdigo) classification) (see appendix d) * dementia or other neurological conditions * absence of anti-sars-cov2 igm or igg at screening * i2. written informed consent provided by the patient or by a legal representative * i3. biologically confirmed sars-cov-2 infection ≤ 10 days before screening * i4. first onset of covid-19 symptoms ≤ 10 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, fatigue, the new loss of taste or smell * i5. findings in chest-x-ray or chest computed tomography compatible with lower respiratory tract infection\* \* precision for imaging: typical imaging features related to covid-19 * i6. patient admitted to hospital for covid-19, but outside of the intensive care unit * i7. patient requiring low-flow o2 supplementation ≤ 6l/min by mask or nasal prongs at screening * i8. the score of 5 on the who 11-point clinical progression scale at screening

inclusion criteria: * i1. male or female ≥ 18 years * greater than or equal to 70 years of age with or without any risk factor * or less than 70 years of age and the presence of at least one of the following risk factors: * arterial hypertension under treatment (all stages) * obesity (body mass index \[bmi\] ≥30 kg/m²) or severe obesity (bmi of ≥40 kg/m²) * diabetes (all types) * heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension) * stroke or cerebrovascular disease history * chronic lung diseases, including copd (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertension * malignancies (solid tumors or blood malignancies) that are progressive or were diagnosed less than 5 years ago * immunocompromised state (this includes patients who are suffering from primary immunodeficiencies; patients under treatment with corticosteroids either oral or parenteral; patients receiving active chemotherapy; patients on biological treatment or treatment with janus kinase (jak) inhibitors) * solid organ or blood stem cell transplant * down syndrome * known human immunodeficiency virus (hiv) infection * liver disease of stage 1 and 2 based on the child-pugh classification (appendix c) * hemoglobin blood disorders (thalassemia, sickle cell disease, etc) * renal disease (grade 1 and 2 according to kidney disease improving global outcomes (kdigo) classification) (see appendix d) * dementia or other neurological conditions * absence of anti-sars-cov2 igm or igg at screening * i2. written informed consent provided by the patient or by a legal representative * i3. biologically confirmed sars-cov-2 infection ≤ 10 days before screening * i4. first onset of covid-19 symptoms ≤ 10 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, fatigue, the new loss of taste or smell * i5. findings in chest-x-ray or chest computed tomography compatible with lower respiratory tract infection\* \* precision for imaging: typical imaging features related to covid-19 * i6. patient admitted to hospital for covid-19, but outside of the intensive care unit * i7. patient requiring low-flow o2 supplementation ≤ 6l/min by mask or nasal prongs at screening * i8. the score of 5 on the who 11-point clinical progression scale at screening

inclusion criteria: i1. male or female ≥ 18 years greater than or equal to 70 years of age with or without any risk factor or less than 70 years of age and the presence of at least one of the following risk factors: arterial hypertension under treatment (all stages) obesity (body mass index [bmi] ≥30 kg/m²) or severe obesity (bmi of ≥40 kg/m²) diabetes (all types) heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension) stroke or cerebrovascular disease history chronic lung diseases, including copd (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertension malignancies (solid tumors or blood malignancies) that are progressive or were diagnosed less than 5 years ago immunocompromised state (this includes patients who are suffering from primary immunodeficiencies; patients under treatment with corticosteroids either oral or parenteral; patients receiving active chemotherapy; patients on biological treatment or treatment with janus kinase (jak) inhibitors) solid organ or blood stem cell transplant down syndrome known human immunodeficiency virus (hiv) infection liver disease of stage 1 and 2 based on the child-pugh classification (appendix c) hemoglobin blood disorders (thalassemia, sickle cell disease, etc) renal disease (grade 1 and 2 according to kidney disease improving global outcomes (kdigo) classification) (see appendix d) dementia or other neurological conditions absence of anti-sars-cov2 igm or igg at screening i2. written informed consent provided by the patient or by a legal representative i3. biologically confirmed sars-cov-2 infection ≤ 10 days before screening i4. first onset of covid-19 symptoms ≤ 10 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, fatigue, the new loss of taste or smell i5. findings in chest-x-ray or chest computed tomography compatible with lower respiratory tract infection* * precision for imaging: typical imaging features related to covid-19 i6. patient admitted to hospital for covid-19, but outside of the intensive care unit i7. patient requiring low-flow o2 supplementation ≤ 6l/min by mask or nasal prongs at screening i8. the score of 5 on the who 11-point clinical progression scale at screening

inclusion criteria: i1. male or female ≥ 18 years greater than or equal to 70 years of age with or without any risk factor or less than 70 years of age and the presence of at least one of the following risk factors: arterial hypertension under treatment (all stages) obesity (body mass index [bmi] ≥30 kg/m²) or severe obesity (bmi of ≥40 kg/m²) diabetes (all types) heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension) stroke or cerebrovascular disease history chronic lung diseases, including copd (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertension malignancies (solid tumors or blood malignancies) that are progressive or were diagnosed less than 5 years ago immunocompromised state (this includes patients who are suffering from primary immunodeficiencies; patients under treatment with corticosteroids either oral or parenteral; patients receiving active chemotherapy; patients on biological treatment or treatment with janus kinase (jak) inhibitors) solid organ or blood stem cell transplant down syndrome known human immunodeficiency virus (hiv) infection liver disease of stage 1 and 2 based on the child-pugh classification (appendix c) hemoglobin blood disorders (thalassemia, sickle cell disease, etc) renal disease (grade 1 and 2 according to kidney disease improving global outcomes (kdigo) classification) (see appendix d) dementia or other neurological conditions absence of anti-sars-cov2 igm or igg at screening i2. written informed consent provided by the patient or by a legal representative i3. biologically confirmed sars-cov-2 infection ≤ 10 days before screening i4. first onset of covid-19 symptoms ≤ 10 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, fatigue, the new loss of taste or smell i5. findings in chest-x-ray or chest computed tomography compatible with lower respiratory tract infection* * precision for imaging: typical imaging features related to covid-19 i6. patient admitted to hospital for covid-19, but outside of the intensive care unit i7. patient requiring low-flow o2 supplementation ≤ 6l/min by mask or nasal prongs at screening i8. the score of 5 on the who 11-point clinical progression scale at screening